Plant ID: NPO14834
Plant Latin Name: Trachelospermum asiaticum
Taxonomy Genus: Trachelospermum
Taxonomy Family: Apocynaceae
NCBI TaxonomyDB:
276781
Plant-of-the-World-Online:
82528-1
Bangladesh; Myanmar; South Africa; Thailand; India; Vietnam; China; Laos; Japan; South Korea; Taiwan
TSHR; NPSR1; | |
ACHE; | |
MAP2K1; MET; AXL; FLT3; CDK1; PIM1; KDR; IGF1R; AURKB; CSNK2A1; | |
CA12; CA7; CA4; | |
ESR2; | |
ALOX12; HSD17B1; AKR1B1; HSD17B10; AKR1B10; NOX4; POLB; | |
KDM4E; | |
MMP9; MMP1; MMP2; | |
NFKB1; | |
FUT7; | |
LMNA; THPO; |
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|---|---|---|---|
Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
Enzyme_unclassified | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | P14061 | CHEMBL3181 |
Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
Enzyme_unclassified | AKR1B10 | Aldo-keto reductase family 1 member B10 | O60218 | CHEMBL5983 |
Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
Metallo protease | MMP9 | Matrix metalloproteinase 9 | P14780 | CHEMBL321 |
Metallo protease | MMP1 | Matrix metalloproteinase-1 | P03956 | CHEMBL332 |
Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
Protein Kinase | MAP2K1 | Dual specificity mitogen-activated protein kinase kinase 1 | Q02750 | CHEMBL3587 |
Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
Protein Kinase | AXL | Tyrosine-protein kinase receptor UFO | P30530 | CHEMBL4895 |
Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
Protein Kinase | CDK1 | Cyclin-dependent kinase 1 | P06493 | CHEMBL308 |
Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
Transferase | FUT7 | Alpha-(1,3)-fucosyltransferase 7 | Q11130 | CHEMBL3596077 |
Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
MF | GO:0005488; binding | GO:0019825; oxygen binding | 2.490E-10 | 2.710E-06 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, NOX4 |
BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 2.372E-09 | 9.697E-06 | CYP1A1, CYP1A2, CYP1B1, CYP2C19 |
BP | GO:0009987; cellular process | GO:0043066; negative regulation of apoptotic process | 3.579E-08 | 4.584E-05 | AKR1B1, ALOX12, AURKB, AXL, CDK1, CSNK2A1, IGF1R, KDR, LMNA, MMP9, NFKB1, PIM1 |
BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 6.660E-08 | 5.801E-05 | CYP1A1, CYP1A2, CYP1B1, CYP2C19 |
MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 9.827E-08 | 8.119E-05 | CYP19A1, CYP1A1, CYP1A2, CYP1B1 |
MF | GO:0005488; binding | GO:0020037; heme binding | 1.478E-07 | 1.038E-04 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, NOX4 |
MF | GO:0005488; binding | GO:0005506; iron ion binding | 5.528E-07 | 2.936E-04 | ALOX12, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19 |
BP | GO:0008152; metabolic process | GO:0018108; peptidyl-tyrosine phosphorylation | 1.334E-06 | 5.480E-04 | AXL, FLT3, IGF1R, KDR, MAP2K1, MET |
BP | GO:0008152; metabolic process | GO:0046777; protein autophosphorylation | 1.809E-06 | 6.353E-04 | AURKB, CSNK2A1, FLT3, IGF1R, KDR, PIM1 |
MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 2.897E-06 | 9.144E-04 | CA12, CA4, CA7 |
BP | GO:0009987; cellular process | GO:0070301; cellular response to hydrogen peroxide | 5.498E-06 | 1.596E-03 | AKR1B1, AXL, CDK1, CYP1B1 |
BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 1.116E-05 | 2.859E-03 | CYP1A1, CYP1A2, CYP1B1 |
BP | GO:0032502; developmental process | GO:0031100; animal organ regeneration | 1.324E-05 | 3.134E-03 | AXL, CDK1, CSNK2A1, FLT3 |
BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 2.137E-05 | 4.700E-03 | CYP1A1, CYP1A2 |
MF | GO:0003824; catalytic activity | GO:0008395; steroid hydroxylase activity | 3.716E-05 | 7.707E-03 | CYP19A1, CYP1A1, CYP2C19 |
BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 4.422E-05 | 8.754E-03 | CA12, CA4, CA7 |
Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|---|
09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 3.263E-08 | 4.601E-06 | HSD17B1, CYP1A1, CYP1B1, CYP19A1, IGF1R |
09160 Human Diseases | 09161 Cancers | hsa05200 | Pathways in cancer | 5.240E-07 | 2.463E-05 | MAP2K1, FLT3, MMP1, MMP2, MET, MMP9, NFKB1, IGF1R |
09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 6.982E-08 | 4.922E-06 | HSD17B1, CYP1A2, CYP1A1, CYP1B1, CYP19A1 |
09160 Human Diseases | 09161 Cancers | hsa05205 | Proteoglycans in cancer | 1.816E-06 | 5.122E-05 | MAP2K1, MMP2, KDR, MMP9, MET, IGF1R |
09160 Human Diseases | 09161 Cancers | hsa05219 | Bladder cancer | 9.557E-07 | 3.369E-05 | MAP2K1, MMP1, MMP2, MMP9 |
09160 Human Diseases | 09161 Cancers | hsa05221 | Acute myeloid leukemia | 3.650E-06 | 7.842E-05 | MAP2K1, FLT3, PIM1, NFKB1 |
09160 Human Diseases | 09161 Cancers | hsa05206 | MicroRNAs in cancer | 1.609E-05 | 2.521E-04 | MAP2K1, PIM1, CYP1B1, MMP9, MET, NFKB1 |
09150 Organismal Systems | 09152 Endocrine system | hsa04915 | Estrogen signaling pathway | 3.291E-05 | 4.218E-04 | MAP2K1, MMP2, MMP9, ESR2 |
09160 Human Diseases | 09161 Cancers | hsa05202 | Transcriptional misregulation in cancer | 1.928E-05 | 2.718E-04 | FLT3, MMP9, MET, NFKB1, IGF1R |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04014 | Ras signaling pathway | 5.843E-05 | 6.034E-04 | MAP2K1, KDR, MET, NFKB1, IGF1R |
Unclassified | Unclassified | hsa01100 | Metabolic pathways | 5.991E-05 | 6.034E-04 | FUT7, AKR1B10, HSD17B1, CYP1A2, CYP1A1, AKR1B1, ALOX12, CYP2C19, CYP19A1, HSD17B10 |
09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 1.564E-05 | 2.521E-04 | CYP1A2, CYP1A1, CYP1B1, CYP2C19 |
09100 Metabolism | 09105 Amino acid metabolism | hsa00380 | Tryptophan metabolism | 5.493E-05 | 6.034E-04 | CYP1A2, CYP1A1, CYP1B1 |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04151 | PI3K-Akt signaling pathway | 3.896E-04 | 2.747E-03 | MAP2K1, KDR, MET, NFKB1, IGF1R |
09160 Human Diseases | 09161 Cancers | hsa05218 | Melanoma | 3.055E-04 | 2.561E-03 | MAP2K1, MET, IGF1R |
09160 Human Diseases | 09161 Cancers | hsa05230 | Central carbon metabolism in cancer | 2.573E-04 | 2.419E-03 | MAP2K1, FLT3, MET |
09150 Organismal Systems | 09152 Endocrine system | hsa04917 | Prolactin signaling pathway | 3.184E-04 | 2.561E-03 | MAP2K1, NFKB1, ESR2 |
09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 3.893E-06 | 7.842E-05 | CA12, CA4, CA7 |
09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04510 | Focal adhesion | 5.139E-04 | 3.450E-03 | MAP2K1, KDR, MET, IGF1R |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04015 | Rap1 signaling pathway | 6.053E-04 | 3.711E-03 | MAP2K1, KDR, MET, IGF1R |
09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04520 | Adherens junction | 3.451E-04 | 2.561E-03 | CSNK2A1, MET, IGF1R |
09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 3.316E-04 | 2.561E-03 | CYP1A2, CYP1A1, CYP1B1 |
09160 Human Diseases | 09161 Cancers | hsa05215 | Prostate cancer | 5.932E-04 | 3.711E-03 | MAP2K1, NFKB1, IGF1R |
09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 8.574E-04 | 4.836E-03 | MMP2, PIM1, NFKB1 |
09150 Organismal Systems | 09152 Endocrine system | hsa04914 | Progesterone-mediated oocyte maturation | 7.855E-04 | 4.615E-03 | MAP2K1, CDK1, IGF1R |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04668 | TNF signaling pathway | 1.098E-03 | 5.733E-03 | MAP2K1, MMP9, NFKB1 |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04066 | HIF-1 signaling pathway | 9.075E-04 | 4.922E-03 | MAP2K1, NFKB1, IGF1R |
09150 Organismal Systems | 09156 Nervous system | hsa04726 | Serotonergic synapse | 1.156E-03 | 5.823E-03 | MAP2K1, ALOX12, CYP2C19 |
09130 Environmental Information Processing | 09133 Signaling molecules and interaction | hsa04060 | Cytokine-cytokine receptor interaction | 1.411E-03 | 6.417E-03 | THPO, FLT3, KDR, MET |
09140 Cellular Processes | 09143 Cell growth and death | hsa04114 | Oocyte meiosis | 1.514E-03 | 6.671E-03 | MAP2K1, CDK1, IGF1R |
09140 Cellular Processes | 09143 Cell growth and death | hsa04210 | Apoptosis | 2.191E-03 | 8.829E-03 | MAP2K1, LMNA, NFKB1 |
09160 Human Diseases | 09167 Infectious diseases | hsa05161 | Hepatitis B | 2.469E-03 | 9.670E-03 | MAP2K1, MMP9, NFKB1 |
09100 Metabolism | 09101 Carbohydrate metabolism | hsa00052 | Galactose metabolism | 1.402E-03 | 6.417E-03 | AKR1B10, AKR1B1 |
09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 1.310E-03 | 6.370E-03 | CYP1A2, CYP2C19 |
09100 Metabolism | 09101 Carbohydrate metabolism | hsa00040 | Pentose and glucuronate interconversions | 2.017E-03 | 8.363E-03 | AKR1B10, AKR1B1 |
09100 Metabolism | 09101 Carbohydrate metabolism | hsa00051 | Fructose and mannose metabolism | 1.595E-03 | 6.815E-03 | AKR1B10, AKR1B1 |
ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
---|---|---|---|
C00-D49: Neoplasms | Cancer | C00-C96 | PIM1; MET; CDK1; IGF1R; KDR; CSNK2A1; NFKB1; FLT3; ACHE; MMP9; MMP2; |
C00-D49: Neoplasms | Breast cancer | C50 | CDK1; IGF1R; KDR; FLT3; CYP19A1; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | ACHE; |
I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR; |
C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; |
C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR; |
C00-D49: Neoplasms | Gliosarcoma | NA | FLT3; |
C00-D49: Neoplasms | Glioma | C71 | KDR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | MMP1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1; |
I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | KDR; |
C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3; |
C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3; |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE; |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE; |
C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1; |
C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; |
N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1; |
C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1; |
C00-D49: Neoplasms | Solid tumours | C00-D48 | MET; AURKB; IGF1R; KDR; FLT3; MMP9; MMP2; |
C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3; |
C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | KDR; |
C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR; |
C00-D49: Neoplasms | Melanoma | C43 | KDR; |
NA: NA | GIST | NA | FLT3; |
C00-D49: Neoplasms | Non-small-cell lung cancer | NA | KDR; |
C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MET; IGF1R; KDR; AXL; |
C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R; |
G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE; |
C00-D49: Neoplasms | Thyroid cancer | C73 | KDR; TSHR; |
H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; |
C00-D49: Neoplasms | Colorectal cancer | C18-C21 | IGF1R; KDR; FLT3; MMP9; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | MMP2; |
J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3; |
K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET; |
C00-D49: Neoplasms | Ovarian cancer | C56 | KDR; MMP2; |
C00-D49: Neoplasms | Multiple myeloma | C90 | IGF1R; |
G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R; |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R; |
C00-D49: Neoplasms | Renal cancer | C64 | KDR; |
G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE; |
C00-D49: Neoplasms | Pancreatic cancer | C25 | KDR; FLT3; MMP2; |
G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | CDK1; IGF1R; ACHE; |
A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE; |
L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | MMP2; |
C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR; |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE; |
NA: NA | Upper abdominal bloating | NA | ACHE; |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | AKR1B1; |
I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | NPSR1; |
C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR; |
C00-D49: Neoplasms | Gastric cancer | C16 | KDR; |
L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET; |
C00-D49: Neoplasms | Colon cancer | C50 | FLT3; |
G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ACHE; |
C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR; |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | FLT3; |
NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3; |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R; |
C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | KDR; |
H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE; |
C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | KDR; AKR1B1; |
C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR; |
N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1; |
C00-D49: Neoplasms | Prostate cancer | C61 | FLT3; |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | NFKB1; |
C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR; |
C00-D49: Neoplasms | Renal cell carcinoma | NA | KDR; MMP2; |
A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3; |
I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9; |
C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR; |
H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | MMP1; |
N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE; |
K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET; |
NA: NA | Hematopoietic stem cell transplantation | NA | FLT3; |
C00-D49: Neoplasms | Hematological malignancies | C81-C86 | AURKB; |
NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE; |
A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE; |
C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; IGF1R; KDR; |
H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA4; ACHE; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1; |
H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ACHE; AKR1B1; |
C00-D49: Neoplasms | Glioblastoma | NA | FLT3; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | AKR1B1; MMP1; |
C00-D49: Neoplasms | Metastasis | C00-C97 | AXL; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | IGF1R; |
C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | AURKB; FLT3; |
C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; |
C00-D49: Neoplasms | CLL | NA | FLT3; |
K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE; |
C00-D49: Neoplasms | Lung cancer | C33-C34 | MMP2; |
K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | MMP9; |
C00-D49: Neoplasms | Bladder cancer | C67 | CYP19A1; |
C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR; |
C00-D49: Neoplasms | AML | NA | KDR; FLT3; |
C00-D49: Neoplasms | Liver cancer | C22 | IGF1R; KDR; |
C00-D49: Neoplasms | Leukemia | C90-C95 | FLT3; |
G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; |
I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET; |
C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR; |
C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR; |
W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR; |